Lackner Mark 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Jan 3, 2025
Insider Transaction Report
Form 4
Lackner Mark
Chief Scientific Officer
Transactions
- Sale
Common Stock
2025-01-02$3.12/sh−4,411$13,762→ 191,317 total
Footnotes (1)
- [F1]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.